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Stem cell-based disease modeling presents unique opportunities for mechanistic elucidation and
therapeutic targeting. The stable induction of fate-specific differentiation is an essential prerequisite for
stem cell-based strategy. Bone morphogenetic protein 2 (BMP-2) initiates receptor-regulated Smad
phosphorylation, leading to the osteogenic differentiation of mesenchymal stromal/stem cells (MSC) in
vitro; however, it requires supra-physiological concentrations, presenting a bottleneck problem for
large-scale drug screening. Here, we report the use of a double-objective feedback system control (FSC) with
a differential evolution (DE) algorithm to identify osteogenic cocktails of extrinsic factors. Cocktails
containing significantly reduced doses of BMP-2 in combination with physiologically relevant doses of
dexamethasone, ascorbic acid, beta-glycerophosphate, heparin, retinoic acid and vitamin D achieved
accelerated in vitro mineralization of mouse and human MSC. These results provide insight into
constructive approaches of FSC to determine the applicable functional and physiological environment for
MSC in disease modeling, drug screening and tissue engineering.
W
ith the recent advent of rapid advancements in stem cell engineering, personalized cell-based disease
modeling in vitro plays an important role for the mechanistic elucidation of disease pathology and
potential drug screening1. The mesenchymal stromal/stem cell (MSC) is a prototypic stem cell model
exhibiting extensive proliferative ability in an uncommitted state and multi-potent differentiation capability2.
MSCs have been used for disease modeling3,4, tissue engineering5,6 or high-throughput drug screening7,8, where
the predictable fate determination of stem cell differentiation through in vitro manipulations presents a key
strategy. To date, the so-called ‘‘conventional osteogenic factors’’9 have empirically been formulated, containing
ascorbic acid and beta-glycerophosphate with/without dexamethasone. Furthermore, various growth factors and
extrinsic factors have been examined for this purpose10–13.
The application of bone morphogenetic protein-2 (BMP-2) has been explored for the in vitro osteogenic fate-
specific differentiation of stem cells. However, BMP-2 has also been shown to differentiateMSC to other lineages,
such as adipocytes14,15. BMP binds to putative receptors and initiates receptor-regulated Smad phosphorylation.
This immediate downstream event was similarly activated during osteogenic16,17 and adipogenic differentiation18.
BMPs aremultifunctional growth factors in the transforming growth factor super family19. It has been shown that
the effect of BMP-2 can be modulated through different signaling pathways, such as Ras/MARK system,
Hedgehog, cAMP, Notch and Wnt20,21. Therefore, multiple co-factors might interact with the BMP-2 signaling
pathway, collectively contributing to fate-specific differentiation. However, extrinsic factors that effectively and
specifically mediate the differentiation of MSC have not been determined.
The objective of this project was to explore a systematic and computational approach for designing a cocktail of
extrinsic factors to stably achieve osteogenic-fate determination of MSC. We applied a feedback system control
(FSC) method, using a differential evolution (DE) algorithm, to derive osteogenic cocktails without predisposing
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hypotheses. The results showed that FSC rapidly elicited optimized
solutions from numerous cocktail candidates. The identified combi-
nations of concentration-specific extrinsic factors induced the osteo-
genic differentiation of MSC with great efficiency. Surprisingly, one
of the effective cocktails contained only 0.39 ng/mL BMP-2, com-
pared with the frequently reported BMP-2 concentration of 100
ng/mL12,22,23, and yet was capable of activating Smad phosphoryla-
tion, resulting in the accelerated in vitro mineralization of clonal
mouse and primary human MSC.
Results
Feedback system control (FSC) method using a differential evo-
lution (DE) algorithm. FSC rapidly elicits optimized solutions from
numerous candidates with great efficiency. In contrast with empirical
trial-and-error methods, goal-guided FSC involves four steps: (1) set
the physiologically appropriate goals; (2) cautiously select the variable
factors; (3) use a high-integrity stochastic algorithm approach to
efficiently elicit optimized harmonization from numerous candi-
dates; and (4) formulate a comparative discussion between the
results and the physiologic goals. FSC iterations are accomplished
using a repeated loop of the interdependent components: the
experimental evaluation of the response of the biological system
under stimulation and a numerical search algorithm for predicting
an improved drug-dosage combination for the next experimental
feedback test (Figure 1a).
In the present study, two physiologically appropriate goals, or
objective functions, were determined: to facilitate the in vitro osteo-
genic differentiation of MSC and to reduce the dosage of BMP-2.
Therefore, we applied a double-objective FSC method to streamline
the search for appropriate cocktails.
From previous studies concerning mouse bone marrow MSC cell
lines, including C3H10T1/2, MC3T3-E1, C2C12 or ST2 cells10–13
(Supplementary References of Osteogenic Factors), we selected
the following extrinsic factors: BMP-2, synthetic glucocorticoid
(dexamethasone; Dex), ascorbic acid (AA or its derivative ascorbic
acid-2-phosphate; AA2P), beta-glycerophosphate (beta-GP), hep-
arin (Hep), retinoic acid (RA), and 1,25(OH)2D3 (VD3). Some syn-
thetic derivatives, instead of intrinsic biomolecules, were utilized
coincident with conventional osteogenic culture conditions. The
reported doses of each extrinsic factor varied significantly (Supple-
mentary Table S1).
Mouse MSC (D1 ORL UVA [D1] or D1 cell, ATCCH Number:
CRL-12424TM) was selected as a multipotent MSC platform with the
capability of expeditious osteogenic fate determination in vitro10,11,24.
Cell culture medium containing 2% or 10% FBS and 1% antibiotics
was utilized as the control medium (negative control). Control med-
ium containing a cocktail of traditional osteogenic factors (AA2P:
50 mM, beta-GP: 10 mM and Dex: 100 nM) with BMP-2 (100
ng/ml) was used as a positive control (hereafter denoted as the TB
cocktail). To identify the optimal combinatory factors, logarithmic
increment doses within the previously published dose range of each
extrinsic factor were determined and described as code (Table 1). As
a result, these 7 factors and 1 to 10 dose levels or 0 to 12 dose levels
generated 107 (10.0 million) to 137 (62.7 million) theoretical
combinations.
A high-integrity stochastic DE algorithm was used in this project.
The DE algorithm optimizes problems through iterative improve-
ments in candidate solutions with regard to a given measure of
quality. Moreover, this algorithm mimics natural biological evolu-
tion. In the present study, the following process was performed:
Initially, N (510 to 14) arbitrary drug cocktails were generated (step
1). For each drug cocktail, a mutated drug cocktail was generated
according to a set of mathematical formulae (step 2). Next, the initial
drug cocktail and the mutated drug cocktail were crossed to produce
a crossover cocktail (step 3), herein referred to as the ‘‘test drug
cocktail’’ to emphasize its role in competing against the original
drug cocktail. Upon experimental comparison of the original and
test drug cocktail, the cocktail that produced better system outcomes
(e.g., ALP activity or mineralization index; see below) was selected
and used in the next iteration (step 4). After all of the initial drug
Figure 1 | Schematic diagram of a double objective FSC-DE. (a) Feedback system control (FSC) applied for the identification of combinatory multiple
extrinsic factors to determine the differentiation fate of MSC. (b) Differential evolution (DE) used as the search algorithm in this project. Each color
represents the concentration of each of the seven extrinsic factors, selected from a scale ranging from 1 to 10 or 0 to 12. The combination of these factors
resulted in 107 (10 million) or 137 (62.7 million) theoretical combinations in the present study.
www.nature.com/scientificreports
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cocktails underwent mutation (step 2), crossover (step 3) and selec-
tion (step 4), the first iteration was complete. Steps 2 to 4 were
repeated until the desired drug cocktails were identified
(Figure 1b). In addition, between iterations, the ‘‘selection’’ algo-
rithm was added to prefer the candidate cocktail containing lower
BMP-2 concentrations (Figure 1b).
FSC with alkaline phosphatase assay. We first selected the expres-
sion of alkaline phosphatase (ALP), a widely known osteogenic
biomarker, as one of the objective functions of FSC. We
constructed the following feedback loop: 1) generate the initial
cocktail with a collection of extrinsic factors at arbitrarily selected
dosages; 2) apply the cocktail to MSC in vitro for 3 days; 3) perform
the ALP expression assay; and 4) generate a set of improved new
combinations through a DE search algorithm to stimulate the
biological system in the next iteration.
After 9 iterations with 20 cocktails tested in each iteration, 8 cock-
tails among the deferred 180 cocktails (90 actual cocktails) signifi-
cantly increased ALP expression in D1 cells after 3 days, despite a
lower BMP-2 dosage. However, when tested for in vitro mineraliza-
tion, none of these 8 cocktails produced noticeable Ca21 precipitation
(Figure 2a), indicating that the identified cocktails did not induce the
osteogenic differentiation of MSC. The dose changes along the FSC
iteration course indicated that the ALP expression was associated
with increased concentrations of RA (Supplementary Fig. S1a).
Indeed, 70% of the cocktails generated during FSC, using ALP
expression as the objective function, contained the top 2 maximum
concentrations of RA (Figure 2b). The adult mouse fibroblastic cell
line, L929 (NCTC clone 929 cell, ATCCH Number: CCL-1TM), was
also shown to induce ALP expression with one of the representative
candidate cocktails.
When RA was removed from the cocktail, the ALP expression in
D1 and L929 cells was completely abolished, whereas the removal of
BMP-2 or VD3 had no effect (Supplementary Fig. S1b). Therefore,
the increased ALP expression inMSC and fibroblasts reflected a high
dose of RA in the identified cocktails, which obviously failed to direct
osteogenic differentiation. Notably, this experiment demonstrated
an unintended observation that FSC was in fact capable of rapidly
identifying the optimal cocktail for the objective function of ALP
expression, in which RA doses approached high doses only after
several iterations. However, the identified FSC cocktails did not meet
the physiological goal of inducing MSC osteogenic differentiation.
FSCwith in vitromineralization assay.We selected in vitrominera-
lization as the objective function in the second experiment, based on
measuring the level of Ca21 precipitation in the wells on day 7. In this
search, we examined 24 drug cocktails per iteration. Through 9
iterations, FSC generated a deferred total of 216 cocktails (100
Table 1 | Code and corresponding concentration for the extrinsic factors used in the double-objective FSC search
Code 12 11 10 9 8 7 6 5 4 3 2 1 0 Unit
Extrinsic Factors
AA or AA2P 400 200 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.2 0 mM
VD3 80 40 20 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0.04 0 nM
BMP-2 400 200 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.2 0 ng/ml
Hep 400 200 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.2 0 mg/ml
RA 40 20 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0.04 0.02 0 mM
Dex 800 400 200 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0 nM
beta-GP 80 40 20 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0.04 0 mM
Figure 2 | FSC-DE with ALP assay. (a) Effect of prospective drug cocktails identified with FSC-DE with ALP assay from 10 million potential candidates
for the osteoblastogenesis of D1 cells. The prospective cocktails did not induce in vitromineralization, despite high ALP activity. (b) Correlation between
doses of extrinsic factors in each drug cocktail elicited and used in FSC-DEwith ALP assay against ALP expression inD1 cells. Dots: each drug cocktail. All
data represent the actual measurement values in the FSC-DE process. The highest concentration codes 9 and 10 of RA were involved in 70% of all FSC-
generated cocktails. D1 cells were seeded at 3125/cm2, and the ALP activity was measured on day 3. Note that the prospective drug cocktails in Figure 2a
were narrowed using setting gates with the following criteria: BMP-2 code less than 9 and ALP activity above 1.5. (a, b) Bar graphs and dots show the
mean with/without s.d. of three independent determinations. Each concentration of extrinsic factors represents the one in drug cocktails and does
not include the one in FBS.
www.nature.com/scientificreports
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actual cocktails). Fourteen cocktails demonstrated in vitro Ca21 pre-
cipitation within 7 days, achieving greater than 50% of the minera-
lization index (Ca21 precipitation in D1 cell culture containing a
given cocktail per that with TB) (Figure 3a & Supplementary Fig.
S2). Four of these drug cocktails contained a BMP-2 dosage of 12.5%
or less relative to that in TB, but these cocktails were capable of
inducing in vitro mineralization, even under diluted cell seeding
conditions (Figure 3b).
Themineralization index was positively correlated with increasing
concentrations of AA2P and beta-GP, and inversely correlated with
RA, Hep and VD3. However, BMP-2 and Dex, potent osteogenic
factors, did not show noticeable correlations (Figure 3c).When small
variations of the VD3 doses were introduced, the osteogenic capabil-
ity of one of FSC cocktail, m8T11, was impaired (Figure 3d), suggest-
ing that the identified doses of each factor might play unique roles in
the osteogenic differentiation of MSC.
Characterization of the identified cocktails. The representative
cocktails m8T11 and m4T5 (Table 2) were selected for further
investigation. Taqman-based real-time reverse transcription poly-
merase chain reaction (RT-PCR) showed that both TB and m8T11
induced the early expression of Runx2 and Osx (Day 1) and the
delayed expression of osteocalcin (Ocn) (Day 7) (Figure 4a). The
m4T5 cocktail also induced Runx2 and Osx, albeit with a different
expression pattern. The upregulated ALP expression (Figure 4b) and
the lack of effect on L929 fibroblasts (Supplementary Fig. S3) further
suggested that these cocktails achieved the osteogenic fate
determination of MSC.
BMPs are extrinsic factors that bind to their putative receptors and
initiate the phosphorylation of the receptor-regulated Smads16,
which is critical for stem cell osteogenic differentiation25,26. The
BMP-2 dose (code 2, 0.39 ng/ml) in the m8T11 cocktail was only
1/256 of that in TB (100 ng/ml). Therefore, we examined whether
media containing m4T5 and m8T11 cocktails initiated the BMP-
Smad signaling pathway using antagonist molecules: Noggin, which
interferes with the receptor association of TGF-beta family ligands,
including BMPs; and Dorsomorphin (Dorso), which blocks BMP-
mediated Smad activation27.
Figure 3 | Identification of prospective drug cocktails using FSC-DE with mineralization assay. (a) Arrangement of the drug cocktails in the order of
each mineralization index. The break line represents the threshold mineralization index of 0.5. D1 cells were seeded at 45,000/cm2; once the cells were
confluent, the media were changed to basal media and subsequently changed to media containing each drug cocktail. The Ca21 content was measured on
day 7. (b) Mineralization assay using the prospective cocktails within the following gate and the diluted cell-seeding condition. D1 cells were seeded at
3125/cm2; themedia were changed tomedia containing each drug cocktail on day 1, and the Ca21 content in the well wasmeasured on day 15. Gate: BMP-
2 code less than 8 and mineralization index above 0.5. (c) Correlation between the doses of the extrinsic factors in each drug cocktail against the
mineralization index. Dots: each drug cocktail elicited and used in FSC-DEwithmineralization assay. All data represent actual measurement values in the
FSC-DE process. The dots show themean of three independent determinations. R: Correlation coefficient. Line: Linear correlation. (d) The effect of VD3
modifications in m8T11. Bar graph: quantitative mineralization assay with original m8T11 (VD3 code 2) and modified m8T11 (VD3 code 5 and 7). D1
cells were seeded at 45,000/cm2; once the cells were confluent, themedia were changed to basal media and subsequently changed tomedia containing each
drug cocktail. The mineralized area was measured on day 7. **: P, 0.01 (ANOVAwith a Dunnett’s test). Representative Alizarin red-stained images. (a,
b, d) The bar graphs shows mean with/without s.d. of three independent determinations. Each concentration of extrinsic factors represents the one in
drug cocktails and does not include the one in FBS.
www.nature.com/scientificreports
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Qualitatively, Noggin treatment selectively decreased the small
Alizarin red-positive areas, revealing trabecular patterns (Figure 4c).
Both Noggin and Dorso treatments significantly decreased the in vitro
mineralization of the media containing TB and m4T5 cocktails
(Figure 4c, d). However, the MSC behaviors with m8T11 medium
were different. The significant attenuation of m8T11-induced in vitro
mineralization was only achieved with Dorso, but not with Noggin
(Figure 4c, d). BMP-2 binds to the high affinity receptor, BMP recep-
tor type I (BMPR1), and subsequently recruits BMPR2, resulting in
the formation of a receptor heterodimer or oligomer16. RT-PCR
revealed the early increase and sustained expression of endogenous
Bmp-2 and its receptors, Bmpr1A and Bmpr2, with m8T11 medium.
TB and m4T5 media showed a late increase in the expression of Bmp-
2 and its receptors (Figure 4e).
Osteogenic-fate differentiation of primary human MSC with
m8T11. We investigated whether m4T5 and m8T11 cocktails were
also effective for the osteogenic differentiation of primary human
MSC (hMSC) (Figure 5). Consistent with the results using mouse
MSC D1 cells, we observed that the m8T11 cocktail effectively
induced in vitro mineralization in primary hMSC, while the m4T5
cocktail did not (Figure 5a, 5b). The representative conventional
osteogenic medium containing 250 mM AA2P, 10 mM beta-GP,
and 10 or 100 nM Dex (Conv-OM) was less effective than the
m8T11 cocktail in inducing the in vitro mineralization of hMSC.
Discussion
This study demonstrated the use of a double-objective FSC technique
for the rapid identification of supplement combinations exhibiting
the versatile osteogenic differentiation of MSC. The FSC strategy has
previously been used for eradicating viral infections28, controlling
herpes virus reactivation29, and maintaining human ES cells30. This
method facilitates the identification of optimal drug combinations
without any predisposing hypotheses. A recent study reported the
unintended FSC-mediated selection of drug cocktails predominantly
containing Ribavirin at high doses using HSV-1-infected NIH3T3
fibroblasts as a biological assay model. We similarly experienced that
the FSC iterations using ALP expression as a biological assay model
converged high dose RA as a single effective factor. However, in the
present study, these FSC cocktails did not induce the intended
physiological outcome of MSC osteogenic differentiation. These
results underscore the robust effectiveness of FSC but indicate the
limitations of this strategy due to the sensitivity and disproportionate
reliance on the biological assay design.
Using in vitro mineralization as an alternative objective function,
we successfully identified two extrinsic factor combinations, m4T5
and m8T11. The FSC formula developed for the present study
included the command with the ‘‘code 0’’ or exclusion of the putative
factor. This built-in mechanism facilitated the elimination of com-
ponents that did not contribute to the biological outcome. Indeed,
the identified FSC cocktails, m4T5 and m8T11, did not contain RA
(Table 2), which induced artificial ALP expression. Notably,
both m4T5 and m8T11 induced ALP expression without RA
(Figure 4b), indicating the osteogenic differentiation of MSC.
Mutantmice lackingRunx231,32 or osterix (Osx)33 have been shown
to exhibit the complete arrest of bone formation, suggesting that
these intrinsic factors determine osteogenic fate. Furthermore, the
gene transcription of the osteoblast-specific molecule, osteocalcin
(Ocn), is regulated through Runx2 and Osx34. The early upregulation
of Runx2 and Osx has been used as an indicator of osteogenic dif-
ferentiation. The m8T11 cocktail demonstrated a sequential gene
expression pattern associated with osteogenic differentiation,
whereas m4T5 delayed the expected gene expression (Figure 4a).
Notably, m4T5 andm8T11 contained 12.5 and 0.39 ng/mL BMP-
2, respectively, compared with the 100 ng/mL BMP-2 concentration
commonly reported for in vitro studies12,22,23 (Table 2). Considering
serum BMP-2 levels of 1.0 ng/mL or 0.09 ng/mL in mice and
humans, respectively, the FSC cocktails utilized in the present study
represent a more physiological environment than previously
reported osteogenic conditions. BMP-2 and BMP-7 have been
accepted for marketing to assist ectopic bone formation and bone
repair35. Studies have shown that the supra-physiological dose of
BMP-2 (1.5 mg/mL) required to achieve a therapeutic effect has been
associated, in part, with high healthcare costs and possible serious
side effects that might limit wider clinical use36. The current FSC
iteration demonstrated that in vitro mineralization occurred, irre-
spective of BMP-2 concentration (Figure 3c). Further characteriza-
tion of m4T5 and m8T11 demonstrated the activation of BMP-2
receptor-regulated Smad cascade (Figure 4c and 4d), suggesting that
BMP-2 elicited the expected effects, despite low concentrations.
Studies evaluating the effectiveness of BMPs and Dex have shown
that rodent and human MSC responded differently to osteogenic
Table 2 | Concentration of Osteogenic Factors in Physiologic Serum/Plasma and Differentiation Media
Physiological
concentration in
mouse serum
(plasma)
Physiological
concentration in
human serum
(plasma)
Conventional
concentration
reported in the
literature*
TBi
medium
(without
FBS)
m4T5i
medium
(without
FBS)
m8T11i
medium
(without
FBS)
2% FBS 10% FBS
AA or AA2P (mM) 44.6a, (R1) 51.7a, (R2) 50b, 250b, 238.38a 50b 50b 50b 0.35a, c, f, (R3) 1.75a, c, g, (R3)
VD3 (nM) 0.102(R4) 0.1(R5) 10 0 0 0.08 0.0008c, f, (R6) 0.0039c, g, (R6)
BMP-2 (ng/mL) 1(R7) 0.09(R8) 100 100 12.5 0.39 0.012f, (R9) 0.06g, (R9)
Hep (mg/mL) - 1 , 2.4c, (R10) 10 0 0 0.39 - -
RA (nM) ,2(R11), 3.6(R12) 4.6(R12), ,14(R13) 1000 0 0 0 0.72 , 1.26f, (R14) 3.6 , 6.2(R14)
GC or Dex (nM) 87 , 320c, d, (R15, 16) 200e, (R17) 10 100 0.39 200 1.7c, d, f,(R18),
4c, e, f, (R18)
8.5c, d, g,(R18),
20c, e, g, (R18)
Serum phosphate 2.7h, (R19) 0.8 , 1.4h, (R20) 10 10 10 10 0.046h, f, (R21) 0.23h, g, (R21)
or beta-GP (mM)
aAs AA.
bAs AA2P; The effective concentration of AA2P for human osteoblast-like cell is similar to that of AA (R22).
cIn plasma.
dAs corticosterone.
eAs cortisol (hydrocortisone).
fOne-fifth or fiftieth of the original number in the reference.
gOne-tenth of the original number in the reference.
hAs serum phosphate or phosphorus.
iBasal media with each drug cocktail; At MSC osteogenic differentiation assay, these media contained 2 and 10% FBS.
*References in the main text and Supplementary references of osteogenic factors.
(R number): Reference number in the Supplementary reference list for Table 2.
GC: Glucocorticoid. The efficacies of the two hormones for osteoblastogenesis are similar to that of Dex (R23, R24).
www.nature.com/scientificreports
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Figure 4 | Osteoblastogenesis induced by m4T5 and m8T11 cocktail and BMP-SMAD signaling pathway. (a) Taqman-based real-time reverse
transcription polymerase chain reaction for Runx2, Osx and Ocn. **: p , 0.01 compared with the control (ANOVA with a Dunnett’s test). (b) ALP
expression in thewellmeasured on day 7. *: p, 0.05 and **: p, 0.01 comparedwith the control (ANOVAwith aDunnett’s test). (c) Alizarin red staining
of D1 cells treated with drug cocktails with/without the following inhibitors: 500 ng/ml of Noggin and 5 mMDorsomorphin (Dorso). The mineralized
matrix was stained with Alizarin red S onDay 7. (d) Quantitative mineralization assay with BMP-SMADpathway inhibitors. **: p, 0.01 compared with
each inhibitor (2) (ANOVAwith a Dunnett’s test). (e) Effect of drug cocktails onmRNA expression of Bmp2, Bmpr2 and Bmpr1A. *: p, 0.05 and **: p
, 0.01 compared with the control (ANOVA with a Dunnett’s test). In all experiments, D1 cells were seeded at 45,000/cm2; once the cells became
confluent, the media were changed to basal media and subsequently changed tomedia containing each drug cocktail. The bar graphs show themean with
s.d. of three independent determinations.
www.nature.com/scientificreports
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differentiation environments in vitro37,38. In the present study, we
also observed the differential effectiveness of the FSC cocktails on
the osteogenic differentiation of humanMSC.While both m4T5 and
m8T11 contained BMP-2, only m8T11 induced the in vitro miner-
alization of human MSC (Figure 5). The m8T11 cocktail contained
the extracellular molecules, Hep and VD3 (Table 2). Hep might
protect BMP-2 fromNoggin and support BMP-2-derived osteogenic
differentiation13, which might partially explain the ineffectiveness of
Noggin in m8T11. VD3 alone39 or the combination of VD3 and
BMP-240 has been shown to increase Ocn expression, whereas a
chromatin immunoprecipitation microarray analysis of MSC
revealed that VDR-derived chromatin remodeling might suppress
gene transcription41,42. It is highly conceivable that the effect of VD3
on the osteogenic differentiation might be dose-sensitive.
The dose of extrinsic factors in the medium containing m8T11
cocktail with FBSwere near the range of physiological concentrations
observed inmouse and human serum (Table 2). Considering that the
identified cocktails contain derivatives instead of biomolecules and
lack various other extrinsic factors, it might be possible to reconstruct
this intact biological osteogenic phenomenon in vivo. However, the
newly identified cocktails might provide a novel opportunity to elu-
cidate the molecular mechanisms of MSC osteogenic differentiation
in a physiologically relevant context.
The recent development of the potential use of induced pluripo-
tent stem cells (iPSC) should broaden the application of the stem cell-
based disease modeling43–45. For example, BMP has been shown to
induce ectopic ossification leading to atherosclerosis46. The signifi-
cantly reduced BMP-2 doses in the identified cocktails and the near-
physiological environment might contribute to the modeling of
vascular cell calcification without potentially confounding the
BMP-2-derived proinflammatory reaction47.
In conclusion, in the present study, we demonstrated the use of a
FSC for the rapid identification of cell culture supplement combina-
tions exhibiting BMP-induced osteogenic differentiation through
extrinsic factors. The outcome of this study might provide a basis
for stem cell-based disease modeling and putative drug development
using high throughput screening.
Methods
Cell maintenance. The mouse MSC line (D1 ORL UVA [D1], D1 cell, CRL-12424),
derived from bonemarrow, and themouse fibroblastic cell line (NCTC clone 929 cell,
L-929 cell, CCL-1), derived from subcutaneous connective tissue, were purchased
from the American Type Culture Collection (ATCC, Manassas, VA, USA). D1 cells
exhibit specific MSC surface markers and are capable of developing osteogenic,
chondrogenic and adipogenic differentiation24. The cells lines were maintained at
subconfluence in Dulbecco’s Modified Essential Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotics in a 5% CO2 incubator at 37uC.
The cells were used for the assays at passages 3 to 6. Primary hMSC, obtained from
normal human bone marrow, were commercially purchased from Lonza
Walkersville, Inc. (Walkersville, MD, USA, Product No PT-2501). The cells were
maintained at subconfluence in MSCGMTM (LonzaWalkersville, Inc., Walkersville,
MD, USA) growth medium in a 5% CO2 incubator at 37uC. According to the
manufacturer’s instructions, the cells at passage 3 (not exceeding passage 5) were used
for assays.
Drug cocktail preparation.Ascorbic acid (AA) or ascorbic acid 2 phosphate (AA2P),
Beta-glycerophosphate (beta-GP), Dexamethasone (Dex), Retinoic acid (RA) and
Heparin (Hep) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
1,25(OH)2D3 (VD3) was obtained from EMDChemicals Inc. (Gibbstown, NJ, USA).
Recombinant human BMP-2 was obtained from R&D Systems (Minneapolis, MN,
USA) and PeproTech (Rocky Hill, NJ, USA). BMP-2 and the other six ingredients at
various concentrations weremixed in DMEM containing 1% antibiotics and FBS (2%
for D1 cell and L929 cell, 10% for hMSC), and these mixtures were used as prototypes
for the media containing drug cocktails. The code of ingredients represents the
concentration of each reagent in the drug cocktails (Table 1).
Quantitative ALP activity assay. ALP activity was determined with a biochemical
colorimetric assay. The cells were briefly washed with PBS and lysed with RIPA
buffer. The enzymatic ALP activity in the lysate was assayed by measuring the p-
nitrophenol formed from the enzymatic hydrolysis of p-nitrophenylphosphate, as a
substrate, at 405 nm. In some cases, ALP data were normalized against the total
protein quantity measured using the BCA protein assay reagent kit (Pierce, Rockford,
IL, USA).
Quantitative real-time PCR. Total RNA fromD1 cell cultures was isolated using the
RNeasy Plus Mini Kit (Qiagen Inc., Valencia, CA, USA). The steady-state mRNA
levels were determined through TaqMan-based real-time PCR using the Taqman
Gene Expression assay with the following probe/primer combinations: Runx2,
Mm03003491_m1; Osx, Mm04209856_m1; bone gamma-carboxyglutamic acid-
containing protein (osteocalcin:Ocn), Mm03413826_mH; Bmp2, Mm01340178_m1;
Bmpr1A, Mm00477650_m1; and Bmpr2, Mm00432134_m1, Gapdh,
Mm99999915_g1. The mRNA expression levels were normalized using the
comparative CT method.
Figure 5 | Osteogenic effect of m4T5 and m8T11 for primary human MSC. (a) Alizarin red-stained human MSC cultures treated with TB (containing
100 ng/mL BMP-2), FSC cocktails m4T5 or m8T11, or conventional osteogenic media (Conv-OM: containing 10 nM or 100 nM Dex). On culture day
15, them8T11 cocktail induced alizarin red-positivemineralized nodules, whilem4T5 did not. (b) The alizarin red-positive areameasurement (excluding
the peripheral ring) suggested that the effect of m8T11 on the osteogenic differentiation of human MSC was approximately 50% of that with TB and
greater than 300% of that with Conv-OM.
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Quantitative Ca21 assay and mineralization index. Ca21 accumulation in each well
was evaluated as the degree of mineralization. The cells were washed twice with PBS
and decalcified with 0.5 NHCl, and the cell culture plates were rotated for 4 h at 4uC.
The Ca21 content in the supernatant was estimated against the standard provided in
the LiquiColor kit (Stanbio Laboratories, Boerne, Texas, USA). The reaction between
Ca21 and ortho-cresolpthalein complex produces a purple complex measured at
550 nm, and the color intensity is directly proportional to the concentration of
calcium in the sample. Basal DMEM with FBS and antibiotics were utilized as the
control medium (negative control). TB: Control medium containing traditional
osteogenic factors (50 mMAA2P, 10 mMbeta-GP and 100 nMDex) with a high dose
BMP-2 (100 ng/ml) was adopted as a benchmark. The mineralization indexes were
calculated using the quantity of Ca21 accumulation induced by the samples per those
of TB.
Alizarin red staining. To evaluate the mineralized bone nodules, the cultured cells
were stained with Alizarin red S (Sigma-Aldrich, St. Louis, MO, USA). The cell layers
were fixed in absolute ethanol for 10 min, washed with ddH2O, and stained with 1%
Alizarin red S. After 30 min, the cell layers were repeatedly washed with ddH2O. The
images were captured using a CanonA495 camera. The prescribed central parts of the
wells were scanned and analyzed using Image J software to quantify the average
percentage of mineralization area against the surface area (i.e., Edges of the wells were
excluded from this calculation).
BMP/SMAD signaling pathway inhibitors. Murine Noggin was purchased from
Pepro Tech (Rocky Hill, NJ, USA). Dorsomorphin (Dorso) was obtained from
Calbiochem (San Diego, CA, USA). The cells were treated with drug cocktails
containing 500 ng/ml of noggin or 5 mM Dorso to determine whether the BMP-
SMAD signaling pathway is involved in the osteoblastogenesis induced through the
drug cocktails.
Feedback system control (FSC) with differential evolution (DE) algorithm. FSC
was performed as follows: D1 cells were stimulated with different drug cocktails. The
level of ALP activity or mineral index wasmeasured and used as an objective function
to observe the osteogenic effect of each drug cocktail. The results were fed into the DE
stochastic search algorithm, which elicited the composition of the new drug cocktail
candidates for the next bioassay. MATLAB software (MathWorks Inc., Natick, MA,
USA)was used to code theDE algorithm, in which each drug cocktail was represented
as a vector. We used a coded dosage instead of the absolute concentration. The new
drug cocktails were manually prepared and utilized to perform the next bioassay, and
this process was repeated until the optimal drug cocktails were obtained.
Statistical analysis. Statistical significance was assessed using one-way analysis of
variance, followed by Dunnett’s multiple comparisons test. The Microsoft Excel
software statistic package was used for the calculation.
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